Role of low-molecular-weight heparins in the management of patients with unstable angina pectoris and non-Q-wave acute myocardial infarction (Q33904621)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Role of low-molecular-weight heparins in the management of patients with unstable angina pectoris and non-Q-wave acute myocardial infarction	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

1 reference

Europe PubMed Central

Role of low-molecular-weight heparins in the management of patients with unstable angina pectoris and non-Q-wave acute myocardial infarction (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

unstable angina

1 reference

based on heuristic

inferred from title

author name string

Monrad ES

1

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

language of work or name

0 references

publication date

1 April 2000

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

American Journal of Cardiology

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

85

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

8A

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

2C-9C

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900879-1

7 January 2021

Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900879-1

7 January 2021

Molecular bases of the acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900879-1

7 January 2021

Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900879-1

7 January 2021

Increased plasminogen activator inhibitor-1 and vasculopathy. A reconcilable paradox

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900879-1

7 January 2021

Mast cells in rupture-prone areas of human coronary atheromas produce and store TNF-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900879-1

7 January 2021

Accumulation of activated mast cells in the shoulder region of human coronary atheroma, the predilection site of atheromatous rupture

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900879-1

7 January 2021

Seminars in medicine of the Beth Israel Hospital, Boston. Platelet-endothelium interactions.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900879-1

7 January 2021

Macrophages, smooth muscle cells, and tissue factor in unstable angina. Implications for cell-mediated thrombogenicity in acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900879-1

7 January 2021

Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900879-1

7 January 2021

Tissue-factor antigen and activity in human coronary atherosclerotic plaques

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900879-1

7 January 2021

Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900879-1

7 January 2021

Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900879-1

7 January 2021

Increased neutrophil-platelet adhesion in patients with unstable angina

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900879-1

7 January 2021

Coronary arteriographic findings soon after non-Q-wave myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900879-1

7 January 2021

Coronary angioscopy in patients with unstable angina pectoris

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900879-1

7 January 2021

Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900879-1

7 January 2021

Low-molecular-weight heparins

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900879-1

7 January 2021

Prolonged antithrombin activity of low-molecular-weight heparins. Clinical implications for the treatment of thromboembolic diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900879-1

7 January 2021

Highly variable anticoagulant response after subcutaneous administration of high-dose (12,500 IU) heparin in patients with myocardial infarction and healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900879-1

7 January 2021

Subcutaneous heparin during coronary thrombolysis. Too little, too late

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900879-1

7 January 2021

Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900879-1

7 January 2021

A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900879-1

7 January 2021

Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900879-1

7 January 2021

Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900879-1

7 January 2021

Low-molecular-weight heparin: is small beautiful?

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900879-1

7 January 2021

Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900879-1

7 January 2021

Role of Thrombin Compared With Factor Xa in the Procoagulant Activity of Whole Blood Clots

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900879-1

7 January 2021

Aspirin, heparin, or both to treat acute unstable angina

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900879-1

7 January 2021

Randomised comparison of subcutaneous heparin, intravenous heparin, and aspirin in unstable angina. Studio Epoorine Sottocutanea nell'Angina Instobile (SESAIR) Refrattorie Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900879-1

7 January 2021

Reactivation of unstable angina after the discontinuation of heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900879-1

7 January 2021

Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900879-1

7 January 2021

Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC)

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900879-1

7 January 2021

A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900879-1

7 January 2021

Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900879-1

7 January 2021

Reduction of reinfarction and angina with use of low-molecular-weight heparin therapy after streptokinase (and heparin) in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900879-1

7 January 2021

Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Even

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900879-1

7 January 2021

Thrombolysis: the need for a critical review.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900879-1

7 January 2021

Our endangered integrity--it can only get worse

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900879-1

7 January 2021

Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900879-1

7 January 2021

Identification of active tissue factor in human coronary atheroma

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900879-1

7 January 2021

Low molecular weight heparin in prevention of restenosis after angioplasty. Results of Enoxaparin Restenosis (ERA) Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900879-1

7 January 2021

Fish oils and low-molecular-weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty. The EMPAR Study

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900879-1

7 January 2021

Effect of nadroparin, a low-molecular-weight heparin, on clinical and angiographic restenosis after coronary balloon angioplasty: the FACT study. Fraxiparine Angioplastie Coronaire Transluminale

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900879-1

7 January 2021

The Subcutaneous Heparin and Angioplasty Restenosis Prevention (SHARP) trial. Results of a multicenter randomized trial investigating the effects of high dose unfractionated heparin on angiographic restenosis and clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900879-1

7 January 2021

A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2800%2900879-1

7 January 2021

Identifiers

10.1016/S0002-9149(00)00879-1

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33904621&oldid=1629642189"